Patent Reform Modifications Clear Congress, But Leave Two Contentious Issues Unresolved
Executive Summary
Congress passes a bill making technical corrections to the America Invents Act; a provision that would have revised the patent term on pending pre-GATT applications was dropped while language restricting litigation following post-grant review was left intact.
You may also be interested in...
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.
White House Credits Eli Lilly With Help In Final Deal On Patent Reform Bill
At President Obama's urging the CEOs of Lilly and Cisco met with Commerce Department officials to hammer out their differences to get the legislation through Congress.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.